Web TV www.labourseetlavie.com : Patrice Demay, Welcome. Patrice Demay – Member Of The Management Board SII : ‘Thank you’ Web TV www.labourseetlavie.com : We’re going to discuss your perspective on the current financial year 2017-2018 performance. We’d like to discuss engineering consulting services with you. Has the company achieved growth in this domain? Patrice Demay […]
Onxeo Just Announced Acquisition of DNA Therapeutics and Provides Update on Portfolio. « Onxeo S.A. , an innovative company specializing in the development of orphan oncology therapeutics, today announced that it has reached an agreement to acquire DNA Therapeutics, a privately-held, clinical-stage biopharmaceutical company, for its signal-interfering DNA repair technology, which is directed at overcoming cancer resistance […]
Nicolas Valtille, hello. Nicolas Valtille – Deputy CEO of AKKA Technologies: Hello. You are the Deputy CEO of AKKA Technologies. We’re at the ODDO Forum 2016 where you’re meeting with investors. Best wishes for this new year. How did 2015 go for AKKA? Nicolas Valtille – Deputy CEO of AKKA Technologies: 2015 was a good […]
Web TV www.labourseetlavie.com partner of Oddo Forum 2016 held in Lyon on 7 and 8 January met many leaders to talk about the year 2015 and 2016 outlook . Back to news biotechnology company specializing in the development of innovative protein formulations. My guest to discuss the strategy is Gérard Soula CEO Adocia .
Web TV: Éric Matteucci, hello. Éric Matteucci – SII Chairman: Hello. Web TV: You are the Chairman of SII. We’re going to discuss the company’s figures for the first-half and the outlook. You also sit on the Engineering Advisory Board. How do you think the first-half has gone? Éric Matteucci –SII Chairman: Look, I think it’s […]
SOLUCOM | LCO | FR0004036036 Back in the first half of the consulting firm that conducted in recent months several acquisitions. Market seems to have found his tone , customers especially in the banking sector have begun to reinvest . How is the strategy, with a recent announcement of the proposed acquisition , my guest […]
ABIVAX, société de biotechnologie spécialisée dans la découverte, le développement clinique et la commercialisation de traitements antiviraux et de vaccins, vient d’annoncer le lancement de son introduction en Bourse. Nous parlons de la stratégie de l’entreprise, des candidats médicaments et des perspectives avec Hartmut Ehrlich, le CEO d’ABIVAX. Au sommaire de l’interview TV : Qui est Abivax ? Les produits […]